个人简介
卢伟强主要从事G蛋白偶联受体（GPCR）在肿瘤发生发展中的功能与分子机理研究，以及靶向GPCR的新药研发。目前以第一作者或通讯作者(含共同)身份在Nat Genet, Nat Comm, EMBO Mol Med, Oncogene, Cell Chem Biol, Haematologica, Br J Pharmacol和 J Med Chem等国际知名学术期刊发表研究论文30余篇。申请国内专利18项，获授权8项。多次被Br J Pharmacol, J Med Chem, 和Phytomedicine等药理学一流学术期刊邀请为审稿人。2018年获得第二十二届中国药理学会青年药理学家奖。2019年获得第十六届全国生化与分子药理学学术会议青年优秀论文一等奖。承担了3项国家自然科学基金（主持），2项上海市自然基金（主持），1项上海市生物医药领域科技支撑项目（主持），同时参与国家重点研发计划和国家自然基金重点项目。
教育经历
2004年至2008年，华东理工大学，本科
2008年至2013年，华东理工大学，博士
工作经历
2013年-2017年 华东师范大学生命科学学院，晨晖学者，助理研究员
2018年-2022年 华东师范大学生命科学学院，副研究员
2023年至今 华东师范大学生命科学学院，研究员
荣誉及奖励
2018年第二十二届中国药理学会青年药理学家奖
2019年第十六届全国生化与分子药理学学术会议青年优秀论文一等奖
近期论文
查看导师最新文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
Lu Weiqiang#,*, Yu Weiwei#, He Jiacheng, Liu Wenjuan, Yang Junjie, Lin Xianhua, Zhang Yuanjin, Wang Xin, Jiang Wenhao, Luo Jian, Zhang Qiansen, Yang Huaiyu, Peng Shihong, Yi Zhengfang, Ren Shancheng, Chen Jing, Siwko Stefan, Nussinov Ruth, Cheng Feixiong, Zhang Hankun*, Liu Mingyao*. Reprogramming Immunosuppressive Myeloid Cells Facilitates Immunotherapy for Colorectal Cancer. EMBO Molecular Medicine. 2021 Jan 11;13(1):e12798.
Lu Weiqiang#, Cheng Feixiong#, Yan Weizhong#, Li Xi, Yao Xue, Song Wenqiang, Liu Mingyao, Shen Xu, Jiang Hualiang, Chen Jin, Li Jian*, Huang Jin*.Selective targeting p53WT lung cancer cells harboring homozygous p53 Arg72 by an inhibitor of CypA. Oncogene, 2017, 36(33): 4719-4731.
Cheng Feixiong#, Zhao Junfei#, Wang Yang#, Lu Weiqiang#, Liu Zehui, Zhou Yadi, Martin William, Wang Ruisheng, Huang Jin 9, Hao Tong, Yue Hong, Ma Jing, Hou Yuan, Castrillon Jessica, Fang Jiansong, Lathia Justin, Keri Ruth, Lightstone Felice, Antman Elliott, Rabadan Raul, Hill David, Eng Charis, Vidal Marc, Loscalzo Joseph*. Comprehensive characterization of protein-protein interactions perturbed by disease mutations. Nature Genetics. 2021 Mar;53(3):342-353.
Cheng Feixiong#, Lu Weiqiang#, Liu Chuang#, Fang Jiansong, Hou Yuan, Handy Diane, Wang Ruisheng, Zhao Yuzheng, Yang Yi, Huang Jin, Hill David, Vidal Marc, Charis Eng, Loscalzo Joseph*, A Genome-wide Positioning Systems Network Algorithm for in silico Drug Repurposing. Nature Communications. 2019 Aug 2;10(1):3476.
Wu Dang#, Wang Wanyan#, Chen Wuyan, Lian Fulin, Lang Li, Huang Ying, Xu Yechun, Zhang Naixia, Chen Yinbin, Liu Mingyao, Nussinov Ruth, Cheng Feixiong*, Lu Weiqiang*, Huang Jin*. Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells. Haematologica. 2018,103(9):1472-1483.
Huang Yujie, Fang Jiansong*, Lu Weiqiang*, Wang Zihao, Wang Qi, Jiang Xingwu, Reizes Ofer, Lathia Justin, Nussinov Ruth, Eng Charis, Cheng Feixiong*, Systems Pharmacology-based Uncovering Wogonoside as a Novel Angiogenesis Inhibitor of Triple-Negative Breast Cancer by Targeting Hedgehog Signaling. Cell Chemical Biology, 2019 Aug 15;26(8):1143-1158.e6.
Jiang Xingwu, Chen Si, Zhang Qiansen, Yi Chunyang, He Jiacheng, Ye Xiyun, Liu Mingyao, Lu Weiqiang*. Celastrol is a novel selective agonist of cannabinoid receptor 2 with anti-inflammatory and anti-fibrotic activity in a mouse model of systemic sclerosis. Phytomedicine. 2020 Feb;67:153160.
Yang Jun-Jie, Yu Wei-Wei, Hu Long-Long, Liu Wen-Juan, Lin Xian-Hua, Wang Wei, Zhang Qiansen, Wang Pei-Li, Tang Shuo-Wen, Wang Xin, Liu Mingyao, Lu Weiqiang*, Zhang Han-Kun*. Discovery and Characterization of 1 H-1,2,3-Triazole Derivatives as Novel Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy. Journal of Medicinal Chemistry. 2020 Jan 23;63(2):569-590.
Lu Weiqiang#, Yao Xue#, Ouyang Ping, Dong Ninging, Wu Dong, Jiang Xingwu, Wu Zengrui, Zhang Chen, Xu Zhongyu, Tang Yun, Zou Shien, Liu Mingyao, Li Jian., Zeng Minghua, Lin Ping, Cheng Feixiong*, Huang Jin*.Drug Repurposing of Histone Deacetylase Inhibitors that Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis. Journal of Medicinal Chemistry, 2017, 60(5):1817-1828.
Lu Weiqiang#, Liu Xiaofeng#, Cao Xianwen, Xue Mnegzhu, Liu Kangdong, Zhao Zhengjiang, Shen Xu, Jiang Hualiang, Xu Yufang, Huang Jin*, Li Honglin*. SHAFTS: A Hybrid Approach for 3D Molecular Similarity Calculation. 2. Prospective Case Study in the Discovery of Diverse p90 Ribosomal S6 Protein Kinase 2 Inhibitors to Suppress Cell Migration. Journal of Medicinal Chemistry, 2011, 54(10):3564-3574.
京公网安备 11010802027423号